ORGO (Organogenesis Holdings) Cyclically Adjusted FCF per Share: $-0.21 (As of Mar. 2026)


ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.47
GF Value $3.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Cyclically Adjusted FCF per Share?

Organogenesis Holdings ORGO -0.80% 67 Cyclically Adjusted FCF per Share is $-0.21 as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.08 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Organogenesis Holdings's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.141. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.21 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-08), Organogenesis Holdings's current stock price is $2.47. Organogenesis Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.21. Organogenesis Holdings's Cyclically Adjusted Price-to-FCF of today is .


Organogenesis Holdings  (NAS:ORGO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Organogenesis Holdings Cyclically Adjusted FCF per Share Related Terms


Organogenesis Holdings Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Cyclically Adjusted FCF per Share Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.22

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.26 -0.22 -0.21

ORGO vs TKNO, AKBA, SIGA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Cyclically Adjusted Price-to-FCF falls into.


ORGO
67GF Score
Organogenesis Holdings Inc ORGO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Organogenesis Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.141/330.2130*330.2130
=0.141

Current CPI (Mar. 2026) = 330.2130.

Organogenesis Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 -0.014 243.801 -0.019
201706 -0.022 244.955 -0.030
201709 -0.018 246.819 -0.024
201712 -0.077 246.524 -0.103
201803 -0.070 249.554 -0.093
201806 -0.245 251.989 -0.321
201809 -0.344 252.439 -0.450
201812 -0.231 251.233 -0.304
201903 -0.109 254.202 -0.142
201906 -0.147 256.143 -0.190
201909 -0.073 256.759 -0.094
201912 -0.101 256.974 -0.130
202003 -0.206 258.115 -0.264
202006 -0.110 257.797 -0.141
202009 0.028 260.280 0.036
202012 0.136 260.474 0.172
202103 -0.047 264.877 -0.059
202106 0.098 271.696 0.119
202109 0.083 274.310 0.100
202112 0.095 278.802 0.113
202203 -0.041 287.504 -0.047
202206 0.030 296.311 0.033
202209 -0.037 296.808 -0.041
202212 -0.022 296.797 -0.024
202303 -0.096 301.836 -0.105
202306 0.009 305.109 0.010
202309 0.081 307.789 0.087
202312 0.055 306.746 0.059
202403 -0.094 312.332 -0.099
202406 0.022 314.175 0.023
202409 0.046 315.301 0.048
202412 0.058 315.605 0.061
202503 -0.187 319.799 -0.193
202506 -0.288 322.561 -0.295
202509 0.006 324.800 0.006
202512 0.247 324.054 0.252
202603 0.141 330.213 0.141

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.21 mean?
Organogenesis Holdings (ORGO) has a Cyclically Adjusted FCF per Share of $-0.21 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Cyclically Adjusted FCF per Share too high?
Organogenesis Holdings' current Cyclically Adjusted FCF per Share is $-0.21. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Cyclically Adjusted FCF per Share compare to TKNO and AKBA?
Organogenesis Holdings' Cyclically Adjusted FCF per Share of $-0.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Cyclically Adjusted FCF per Share is $-0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.08, compared to a current price of $2.47 — trading 19.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.21. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Cyclically Adjusted FCF per Share is $-0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.47 is trading 19.8% below its estimated GF Value™ of $3.08. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • Cyclically Adjusted FCF per Share: $-0.21
  • GF Value™: $3.08 vs. price of $2.47 (19.8% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.47
Price
$3.08
GF Value